NCT06790797View on ClinicalTrials.gov

Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

February 12, 2023

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2027

Conditions
Lung CancerEsophageal Cancer
Interventions
OTHER

In vitro stimulation of Pbmc with tumor antigen nanoparticles

PBMCs were isolated from peripheral blood of cancer patients, and PBMC are co-incubated with nanoparticles loading tumor antigens for specific time in vitro to detect T cells that are related with efficacy of cancer immunotherapy. The content of such T cells are studies the correlation with the efficacy of cancer immunotherapy and patient prognosis.

Trial Locations (1)

215000

RECRUITING

The first affiliated hospital of soochow university, Suzhou

All Listed Sponsors
lead

Zhao Jun

OTHER